A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.12.025
Abstract: BACKGROUND EP0057 (formerly CRLX101) is an investigational nanoparticle-drug conjugate (NDC) of a cyclodextrin-based polymer backbone plus camptothecin, a topoisomerase-1 inhibitor. Prior studies showed efficacy in recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal… read more here.
Keywords: phase; formerly crlx101; ep0057 formerly; paclitaxel ... See more keywords